Payment overview · 2025
General Payments
$277.71
15 reported records · 8 companies
Healthcare provider profile · identity verified
Michael M Dee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NAMPA, ID · NPI 1053302182
Verified facts
What the public records show
CMS Open Payments records show Michael M Dee, M.D. received $277.71 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.17 | 28.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.02 | 24.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.98 | 17.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.98 | 7.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.63 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.74 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.48 | 5.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.71 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.71 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.17 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.17 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 162 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
162 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 682 | 162 |
| Losartan Potassium | Losartan Potassium | 634 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 120 |
| Gabapentin | Gabapentin | 428 | 106 |
| Omeprazole | Omeprazole | 412 | 109 |
| Furosemide | Furosemide | 359 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 75 |
| Metformin Hcl | Metformin Hcl | 301 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 51 |
| Eliquis | Apixaban | 255 | 54 |
| Trazodone Hcl | Trazodone Hcl | 240 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 59 |
| Potassium Chloride | Potassium Chloride | 230 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 57 |
| Lisinopril | Lisinopril | 205 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 53 |
| Sertraline Hcl | Sertraline Hcl | 186 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 45 |
| Farxiga | Dapagliflozin Propanediol | 162 | 28 |
| Meloxicam | Meloxicam | 160 | 40 |
| Ezetimibe | Ezetimibe | 153 | 37 |
| Famotidine | Famotidine | 152 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 148 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 38 |
| Allopurinol | Allopurinol | 145 | 28 |
| Bupropion Xl | Bupropion Hcl | 145 | 26 |
| Tramadol Hcl | Tramadol Hcl | 119 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 29 |
| Alendronate Sodium | Alendronate Sodium | 88 | 21 |
| Spironolactone | Spironolactone | 88 | 26 |
| Estradiol | Estradiol | 85 | 24 |
| Glimepiride | Glimepiride | 83 | 18 |
| Simvastatin | Simvastatin | 83 | 24 |
| Irbesartan | Irbesartan | 81 | 19 |
| Prednisone | Prednisone | 77 | 31 |
| Ozempic | Semaglutide | 75 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Jardiance | Empagliflozin | 72 | 11 |
| Clonazepam | Clonazepam | 68 | 12 |
| Montelukast Sodium | Montelukast Sodium | 66 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 17 |
| Lorazepam | Lorazepam | 64 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 17 |
| Finasteride | Finasteride | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 62 | 19 |
| Alprazolam | Alprazolam | 61 | 14 |
| Carvedilol | Carvedilol | 59 | 15 |
| Celecoxib | Celecoxib | 59 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 24 |
| Bumetanide | Bumetanide | 57 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 25 |
| Cephalexin | Cephalexin | 52 | 34 |
| Myrbetriq | Mirabegron | 50 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 15 |
| Propranolol Hcl | Propranolol Hcl | 45 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 13 |
| Methadone Hcl | Methadone Hcl | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 41 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Nystatin | Nystatin | 37 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 13 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Levetiracetam Er | Levetiracetam | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Zanaflex | Tizanidine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.71 · 15 records | Novo Nordisk Inc | BREZTRI, FARXIGA, JARDIANCE, LEQVIO, Ozempic, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error